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Glucose-6-phosphate dehydrogenase (G6PD) enzyme function and genotype were determined in Ugandan children with uncom-
plicated falciparummalaria enrolled in a primaquine trial after exclusion of severe G6PD deficiency by fluorescent spot test.
G6PD A heterozygotes and hemizygotes/homozygotes experienced dose-dependent lower hemoglobin concentrations after
treatment. No severe anemia was observed.
Declines in malaria due to Plasmodium falciparum have beendocumented in a number of settings where malaria is en-
demic. It is debated whether scaling-up of conventional malaria
control will sustain these declines or achieve elimination unless
augmented by tools that specifically reduce transmission. Pri-
maquine is the only currently available drug that actively clears
mature P. falciparum gametocytes and preventsmalaria transmis-
sion to mosquitoes (1). The wide-scale use of primaquine is ham-
pered by its hemolytic effect in people with glucose-6-phosphate
dehydrogenase (G6PD) deficiency. Themutation deficiency alters
G6PD enzyme function (2), exposing red blood cells to oxidative
stress and resultant hemolysis in the presence of a stressor, such as
primaquine (3, 4). Primaquine-induced hemolysis is dose related
(1, 5, 6). While testing for G6PD deficiency is widely recom-
mended prior to the radical treatment of Plasmodium vivax with
14 days of primaquine, P. falciparum transmissionmay be consid-
erably reduced by a single, low dose of primaquine (1, 7) andmay
avoid the necessity to screen for G6PD deficiency.We determined
G6PD enzyme function and the presence of the most common
African G6PD mutation (G6PD A; 202A/376G) in a cohort of
Ugandan children treated with low-dose primaquine for clearing
P. falciparum gametocytes. This was a randomized, double-
blinded placebo controlled trial with four parallel arms. Ugandan
children 1 to 10 years old with uncomplicated P. falciparum ma-
laria, hemoglobin concentration (Hb) of 8 g/dl, and normal
G6PD enzyme function based on a fluorescent spot test (FST;
R&DDiagnostics, Agia Paraskevi, Greece) were enrolled and ran-
domized to treatmentwith artemether lumefantrine (AL) alone or
with a single dose of primaquine at 0.1, 0.4, or 0.75 mg/kg of body
weight on the last day of AL treatment (7, 8). Genotyping of G6PD
202A and G6PD 376G was performed (9, 10). Hb was measured
on days 0, 1, 2, 3, 7, 10, 14, 21, and 28 after enrollment by
HemoCue 201 (Angelholm, Sweden) and expressed as absolute
and relative change compared to baseline values. These values
were normally distributed, presented usingmean values and stan-
dard deviations, and analyzed using linear regression models. Be-
cause the age distribution of the red blood cell population influ-
ences the severity of drug-induced hemolysis (11), we adjusted all
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TABLE 1 Baseline characteristics
Characteristic
Value by G6PD 202 A genotype
Wild type Heterozygous
P value for
difference from
wild type Homozygous/hemizygous
P value for
difference from
wild type
No. of participants (% study population) 373 (80.9) 61 (13.2) 27 (5.9)
% female (no. of females/total no. of
participants)
46.7 (174/373) 100.0 (61/61) 0.001 3.7 (1/27) 0.001
Mean (SD) age in yrs 5.0 (2.6) 4.8 (2.3) 0.61 4.9 (2.4) 0.86
Mean (SD) baseline Hb concn in g/dl 11.2 (1.5) 11.4 (1.4) 0.20 10.9 (1.4) 0.38
% 376G genotype (no. of participants
with genotype/total no.)
Heterozygous 18.6 (69/371) 78.7 (48/61) 0.0 (0/27)
Homozygous 12.9 (48/371) 21.3 (13/61) 0.001 100.0 (27/27) 0.001
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comparisons for baseline Hb concentration. All trial participants
(n 468) were G6PD normal by FST. DNA was available for 461
individuals of whom 27 (5.9%) were homozygous/hemizygous,
61 were heterozygous (13.2%), and 373 (80.9%) were normal for
the G6PD variant A (wild type [WT]). All individuals with the
202Amutation also had the 376Gmutation, and individuals were
classified based on the 202A mutation (Table 1). G6PD 202 A
heterozygous individuals experienced a mean reduction in Hb
concentration on day 7 after treatment of 1.08 g/dl (standard de-
viation [SD], 1.14; P  0.048) in the 0.75-mg/kg treatment arm
and 0.99 g/dl (SD, 1.48; P  0.054) in the 0.4-mg/kg treatment
arm (Table 2). Homozygous/hemizygous individuals in the 0.75-
mg/kg and 0.4-mg/kg arms also experienced a reduction in abso-
lute Hb concentration on day 7, although this was statistically
significant in the 0.4-mg/kg arm only (P 0.043). When changes
in Hb concentration on day 7 were expressed as a proportion of
baseline Hb concentration, the same trend was observed with sta-
tistically significant decreases in the 0.75-mg/kg arm for heterozy-
gous individuals and in the 0.4-mg/kg arm for homozygous/hem-
izygous individuals. No statistically significant changes in absolute
or relative Hb concentrations were observed for heterozygous or
homozygous/hemizygous individuals in the 0.1-mg/kg arm or
placebo arm (Table 2). We found no explanation for the numer-
ically large, but statistically nonsignificant, reduction in Hb con-
centration in homozygous/hemizygous individuals on day 7 after
receiving AL without primaquine. A previous study found no he-
molysis after AL in homozygous/hemizygous individuals (12),
and we conclude our observation may be a spurious finding and
related to our small sample size. We observed no statistically sig-
nificant associations between G6PD genotype and absolute or rel-
ative Hb concentrations in any treatment arm on days 3 and 10
after initiation of treatment (see the supplemental material). Six-
ty-nine individuals experienced a reduction of2 g/dl in the first
2 weeks of follow-up: 13.7% (51/373) of the WT individuals,
26.2% (16/61; P  0.031) of the heterozygous individuals, and
7.4% (2/27; P 0.48) of the G6PD 202 A homozygous/hemizy-
gous individuals (P  0.020). For all individuals, Hb concentra-
tions normalized during follow-up. The current findings provide
important data on the hemolytic effect of single-, low-dose prim-
aquine. Our results show that the predominant test for G6PD
deficiency screening, the FST (13), failed to identify a substantial
proportion of individuals whowere genotypicallyG6PDdeficient,
particularly female heterozygotes, who experienced significant re-
ductions in hemoglobin following higher doses of primaquine.
The observation that some G6PD-deficient individuals were FST
normal is unsurprising since the test may be insufficiently sensi-
tive to detect mild G6PD deficiency (13), but there are few
supportive published data. We observed statistically significant
decreases inHb following single-dose primaquine in these G6PD-
deficient individuals. A hemolytic effect of a single dose of 0.75
mg/kg primaquine base has been reported before (6); our study
shows that a reduction in Hb concentrations is also evident after a
single dose of 0.4 mg/kg but not 0.1 mg/kg. Moreover, reductions
in Hb were transient, with no participant experiencing clinical
symptoms suggestive of anemia and none requiring related clini-
cal care. Although these findings are notable, amajor limitation of
the study is that individuals who were determined G6PD deficient
based on the FST were excluded from the study (n 32), thereby
plausibly removing those most severely deficient and thereby
those with the highest risk of primaquine-induced hemolysis.
There is therefore a need for confirmatory trials to formally assess
primaquine safety in G6PD-deficient individuals, in particular
with the World Health Organization recommended dose of 0.25
mg/kg. Such studies will have to take into account interindividual
differences in primaquinemetabolism that determine primaquine
efficacy in P. vivax (14) and potentially also safety.
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TABLE 2 G6PD 202 A genotype and hemoglobin levelsa
Characteristic
Value by treatment arm
0.75 mg/kg primaquine 0.4 mg/kg primaquine 0.1 mg/kg primaquine Placebo
No. of study participants
G6PD normal 98 90 93 92
G6PD heterozygous 14 13 16 18
G6PD hemizygous/homozygous 4 10 6 7
Mean absolute change (SD) in Hb on day 7
G6PD normal, in g/dl 0.41 (0.95) 0.25 (1.22) 0.30 (1.07) 0.11 (1.33)
G6PD heterozygous, in g/dl 1.08 (1.14) 0.99 (1.48) 0.07 (0.98) 0.49 (1.40)
P value 0.048 0.054 0.35 0.28
G6PD hemizygous/homozygous, in g/liter 1.10 (1.34) 0.48 (0.76) 0.07 (1.21) 1.02 (0.81)
P value 0.21 0.043 0.91 0.22
% relative change (SD) in Hb on day 7, in g/dl
G6PD normal 3.25 (8.60) 1.28 (11.24) 2.16 (9.71) 0.23 (11.34)
G6PD heterozygous 9.38 (10.4) 7.79 (12.57) 0.01 (8.56) 3.26 (12.26)
P value 0.044 0.073 0.34 0.33
G6PD hemizygous/homozygous 7.97 (12.40) 4.29 (7.70) 0.05 (11.45) 8.59 (7.28)
P value 0.36 0.028 0.93 0.16
a On day 7 after initiation of treatment with artemether-lumefantrine (AL) plus placebo or AL plus different doses of primaquine. All primaquine or placebo treatment was
administered together with six doses of AL; primaquine/placebo was given on day 2 of treatment, together with dose 5 of AL. P values are compared to G6PD-normal individuals,
adjusted for baseline Hb concentration.
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